Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study

Cytotherapy ◽  
2017 ◽  
Vol 19 (4) ◽  
pp. 500-513 ◽  
Author(s):  
Per Kongsted ◽  
Troels Holz Borch ◽  
Eva Ellebaek ◽  
Trine Zeeberg Iversen ◽  
Rikke Andersen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dendritic Cell ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Dendritic Cell Vaccination ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Randomized Phase Ii

Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel

2014 ◽  
Vol 25 (9) ◽  
pp. 1081-1088 ◽  
Author(s):  
Jean-Pierre Droz ◽  
Jaques Medioni ◽  
Christine Chevreau ◽  
Helene De Mont-Serrat ◽  
Michael Merger ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Randomized Phase Ii

scholarly journals A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209

Oncotarget ◽  
2018 ◽  
Vol 9 (8) ◽  
pp. 8155-8164 ◽  
Author(s):  
Bernhard Josef Eigl ◽  
Kim Chi ◽  
Dongsheng Tu ◽  
Sebastien J. Hotte ◽  
Eric Winquist ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Randomized Phase Ii
Sign in / Sign up

Export Citation Format

Share Document